SAN DIEGO, Jan. 23 /PRNewswire/ -- ActiveSight announced that it has signed an agreement with Novo Nordisk A/S to provide protein crystallography services. ActiveSight will co-crystallize Novo Nordisk proprietary molecules with proteins expressed by ActiveSight. Additional details of the agreement were not disclosed.
"We are very pleased to add a company of Novo Nordisk's stature to our growing customer base. We look forward to supplying their scientists with structural information to accelerate their discovery efforts," stated Ronald V. Swanson, Ph.D., Chief Scientific Officer for ActiveSight.
This is the first announced agreement of 2006 for the protein crystallography services provider, which was founded in 2003.
ActiveSight(TM), a division of Rigaku Americas Corporation, features a Portfolio of "ready to go" drug targets for co-crystallography. The Protein Portfolio includes the oncology targets Focal adhesion kinase (FAK), Hsp90 and Aurora-A kinase; nuclear hormone receptor targets PPAR-delta and FXR, implicated in obesity; PDE-4 for asthma and inflammation; the hypertension target Renin; the type-II diabetes target FBPase; and the anti-infective target bacterial DNA gyrase.
ActiveSight also offers full gene-to-structure protein crystallography services for client's targets, including X-ray data collection and fragment-based screening, featuring the Rigaku FR-E and ACTOR automation systems. For more information visit www.active-sight.com.
ActiveSight is a trademark of Rigaku.
CONTACT: Joy Silen, Director of Business Development of ActiveSight,+1-858-455-6870, email@example.com